Lanvin Group Gets NYSE Notice Over Sub-$1.00 Share Price, Has Six Months to Cure
LANV sits 15% above its 52-week low of $0.625.
Summary
Lanvin Group received an NYSE notice on November 10, 2026 that its shares averaged below US$1.00 over 30 trading days, triggering a six-month cure period. To regain compliance, the company says it may pursue a reverse stock split, subject to shareholder approval.
Key Events · Legal and Risk Events · LANV
-
NYSE Minimum Price Notice Received
NYSE notified Lanvin on November 10, 2026 that its ordinary shares averaged below US$1.00 over a consecutive 30 trading-day period, breaching Section 802.01C of the Listed Company Manual.
-
Six-Month Cure Window
The company has six months from receipt to regain compliance, achieved if the closing price is at least US$1.00 on the last trading day of any calendar month and the 30 trading-day average ending that day is also at least US$1.00.
-
Reverse Split Flagged as Option
Lanvin said it will consider available alternatives, including a reverse stock split that would require shareholder approval, if needed to cure the deficiency.
-
Delisting Risk if Cure Fails
If compliance is not regained by the end of the cure period, the NYSE will commence suspension and delisting procedures for the ordinary shares.
Analysis · LANV · Manufacturing
The listing itself is now at risk: Lanvin's ordinary shares have averaged below US$1.00 for 30 straight trading days. To get the price back above US$1.00, the company has until roughly May 2027, and it is already floating a reverse stock split as the likely fix. That matters because a reverse split does not create value — it just shrinks the share count and lifts the quoted price, and it usually comes with fresh selling pressure once the smaller float trades. The notice lands on top of an already weak backdrop: H1 2026 revenue fell 13% to €100.8 million, the net loss was €65.6 million, and the company previously disclosed going-concern language. A delisting would cut LANV off from US institutional capital and index inclusion, so the cure path — and whether shareholders approve a split — is now the central question for the equity.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LANV was trading at $0.72 on NYSE in the Manufacturing sector, with a market capitalization of approximately $90.4M. The 52-week trading range was $0.63 to $2.31. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.